VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
FATEFate Therapeutics, Inc.
$2.09$244M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksFATEEarnings History

FATE logoFate Therapeutics, Inc. (FATE) Earnings History

Net Loss

15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$130M
● Net Loss
TTM EPS (Diluted)
$-1.08
Per share, diluted
YoY EPS Growth
+29.9%
Excellent
Net Margin
-2051.1%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-2222.4%
Gross Margin-94.1%
Return on Equity-51.8%
Return on Assets-35.9%
Record Annual Net Income-$13MFY2011
Record Quarterly EPS$-0.09Q1 2023
Consecutive Profitable Years0years
Q1 2026
Net Income-$31M
EPS (Diluted)$-0.26
YoY Growth+29.9%Excellent
QoQ Growth+3.6%Solid

Loading earnings history...

Fate Therapeutics, Inc. (FATE) Earnings Overview

As of June 22, 2026, Fate Therapeutics, Inc. (FATE) reported trailing twelve-month net income of -$130M, reflecting +29.9% year-over-year growth. The company earned $-1.08 per diluted share over the past four quarters, with a net profit margin of -2051.1%.

Looking at the long-term picture, FATE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2011.

Fate Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including CRSP (-$569M net income, -16569.8% margin), NTLA (-$395M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), FATE has outperformed on profitability metrics. Compare FATE vs CRSP →

FATE Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
FATE logoFATECurrent
-$130M$-1.08-2051.1%-51.8%+29.9%—
CRSP logoCRSP
-$569M$-5.92-16569.8%-30.2%-49.1%
NTLA logoNTLA
-$395M$-3.33-609.9%-53.5%+27.4%
BEAM logoBEAM
-$65M$-0.63-57.2%-8.1%+82.3%
EDIT logoEDIT
-$109M$-1.11-395.0%-198.1%+37.5%
SANA logoSANA
-$242M$-0.87--118.7%+17.2%
Best in group
Lowest in group

FATE Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$136M+26.8%-$148M$-1.15-2051.1%-2222.4%
2024-$186M-15.7%-$210M$-1.64-1366.5%-1542.6%
2023-$161M+42.9%-$191M$-1.64-253.3%-299.9%
2022-$282M-32.8%-$308M$-2.91-292.5%-320.2%
2021-$212M-22.4%-$217M$-2.24-379.9%-388.6%
2020-$173M-76.7%-$128M$-2.10-551.6%-407.5%
2019-$98M-47.4%-$101M$-1.43-919.0%-943.1%
2018-$67M-55.1%-$67M$-1.19-1405.0%-1415.4%
2017-$43M-28.4%-$42M$-1.02-1046.1%-1025.9%
2016-$33M-11.6%-$32M$-1.05-760.2%-726.1%
2015-$30M-15.9%-$28M$-1.18-1233.7%-1142.8%
2014-$26M-23.9%-$25M$-1.27--
2013-$21M-46.7%-$18M$-1.06-2151.8%-1820.3%
2012-$14M-6.0%-$14M$-1.61-533.3%-507.8%
2011-$13M--$13M$-1.51-1147.6%-1136.2%

Download Data

Export FATE earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

FATE — Frequently Asked Questions

Quick answers to the most common questions about buying FATE stock.

What is FATE earnings per share (EPS)?

FATE trailing twelve-month (TTM) diluted EPS is $-1.08, reflecting +29.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is Fate Therapeutics, Inc.'s net income?

Fate Therapeutics, Inc. (FATE) trailing twelve-month net income is $-130M as of 2025. Earnings grew +29.9% year-over-year.

Is FATE profitable?

FATE is not currently profitable on a TTM basis, reporting a net loss of $-130M. Net margin is -2051.1%. Investors should monitor for a return to profitability.

What is FATE's earnings growth rate?

FATE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are FATE's profit margins?

Fate Therapeutics, Inc. net profit margin is -2051.1%, operating margin is -2222.4%, and gross margin is -94.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -51.8%.

Is FATE growing earnings?

Yes, FATE earnings are accelerating — EPS growth of +29.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-130M. Earnings momentum is strengthening.

What was FATE's best earnings year?

Fate Therapeutics, Inc.'s highest annual net income on record is $-13M, achieved in fiscal year 2011. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were FATE's earnings last quarter?

FATE's most recent reported quarter was Q1 2026. Net income was $-31M with diluted EPS of $-0.26. For a full breakdown of all quarters, see the quarterly earnings table on this page.

FATE Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view